The nation of Zimbabwe has turned down a significant American healthcare agreement valued at $367m (272 million pounds) over five years over the United States' request for sensitive data.
This move became public after a internal memorandum from December was disclosed, revealing that Head of State Emmerson Mnangagwa believed the arrangement was "lopsided".
An official spokesperson has since stated that the United States was requesting health data for scientific study and profit but was unwilling to share the benefits from future vaccines.
"We will now turn to the difficult and regrettable task of scaling back our health assistance in Zimbabwe," stated US ambassador to Zimbabwe Pamela Tremont in a statement.
The US Embassy said the United States had provided over $1.9bn for health programmes to Zimbabwe over the last twenty years.
A doctors' association in Zimbabwe has appealed for further talks to reach a agreement agreeable to both sides so the country's critical HIV programme can be sustained.
Broader Background
This development follows a comparable case in neighbouring Kenya, where a high court blocked a similar health funding agreement following legal challenges were raised about the security of citizens' medical information.
After returning to the presidency last year, US President Donald Trump has reduced overseas assistance and closed the key foreign aid agency.
USAID had administered assistance for the American government, but Trump argued its expenditure was "inefficient" and his administration was pursuing direct bilateral deals to boost openness and accountability.
According to statements, 16 nations in Africa have to date agreed to similar agreements, representing more than $18.3bn in committed funds.
Details of the Rejected Deal
The funds for Zimbabwe would have funded "combating HIV/Aids, TB, malaria, maternal and child health, and preparing for epidemics".
"We are confident this collaboration could have provided significant advantages for Zimbabwean communities, especially the 1.2 million presently on HIV treatment via US-supported initiatives," the Ambassador added.
However, official spokesman Nick Mangwana argued the arrangement was "unequal".
"The proposal required Zimbabwe to share its biological resources and data for a long time, with no corresponding guarantee of access to any medical innovations – such as new medicines or tests – that might result from that provided information," his statement read.
"Put simply, our nation would supply the raw materials for scientific discovery with no certainty that the end products would be available to our citizens if a future health crisis emerge."
National Interest and International Frameworks
Mangwana further said that the US's withdrawal from the World Health Organization (WHO) and its push of bilateral deals were disrupting systems previously set up via the international health agency.
The spokesperson cited its Pandemic Benefit-Sharing system designed to deal with potential global health emergencies.
"This framework is intended to guarantee that when a country contributes its data, the benefits – including medicines and cures – are shared equitably, not commercialised exclusively by those with the capability to develop them."
These objections over the US deal "are not meant as opposition to America," he added.
"We are open to ongoing discussions with our US partners on how subsequent collaboration could be designed in a way that respects the sovereignty and interests of both nations."
Health Experts Reaction
A leading public health body expressed it acknowledged the official position, but suggested that negotiations need to persist considering a large portion of the nation's Aids initiatives relied on international support.
"Where specific concerns exist, such as those involving information security or implementation frameworks, these can often be resolved via technical clarification and negotiated safeguards," it added.
The halted deal highlights the ongoing tensions between accepting vital foreign assistance and safeguarding local interests in an ever more data-driven world.